CHARLOTTESVILLE, Va., Sept. 21, 2021 /PRNewswire/ — HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, has earned a milestone payment for the advancement of potential lead product candidates for the treatment of gout under its collaboration with Horizon Therapeutics plc (Nasdaq: HZNP). This milestone marks the fourth payment that HemoShear has earned, following previous payments for the identification and validation of two novel gout drug targets in accordance with the Horizon exclusive drug discovery agreement established in January 2019.
{iframe}https://www.johnsoncitypress.com/hemoshear-therapeutics-prnewsfoto-hemoshear-therapeutics/image_f4f7c3be-74eb-5ac6-ac91-2a2c1903e082.html{/iframe}